New tests launched in November


New Tests

In November 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

The new tests that launched in November 2022 by Mayo Clinic Laboratories:

CDPCR | Clostridioides difficile Toxin, PCR, Feces

This test is intended for sensitive, specific, and rapid diagnosis of Clostridioides (Clostridium) difficile-associated diarrhea and pseudomembranous colitis.

H1083 | HIK1083 Immunostain, Technical Component Only

This test is useful for the diagnosis of gastric-type endocervical adenocarcinoma.

IDH2 | IHD2, R172K Mutation, Immunostain, Technical Component Only

This test is intended to be used for the identification of IDH2 R172K mutant protein in angioimmunoblastic T-cell lymphoma or acute myeloid leukemia.

MALP | Malabsorption Evaluation Panel, Feces

This test is useful for the evaluation of patients with suspected malabsorption, as suggested by chronic diarrhea, unexplained weight loss, or nutritional deficiencies.

MCLBP | MayoComplete Liquid Biopsy Panel, Next-Generation Sequencing, Cell-Free DNA

This test is intended to be used as an alternative to invasive tissue biopsies to assist in tumor profiling for diagnosis, predicting prognosis, and identifying targeted therapies for the treatment and management of patients with solid tumors.

MDSDF | Myelodysplastic Syndrome (MDS), Diagnostic FISH, Varies

This test is useful for detecting a neoplastic clone associated with the common chromosome abnormalities seen in patients with myelodysplastic syndromes or other myeloid malignancies using a laboratory-designated probe set algorithm.

MDSMF | Myelodysplastic Syndrome (MDS), Specified FISH, Varies

This test is useful for detecting a neoplastic clone associated with the common chromosome abnormalities seen in patients with myelodysplastic syndromes or other myeloid malignancies using client specified probes.

POU2F | POU2F3 Immunostain, Technical Component Only

This test is intended to be used for the diagnosis of a variant of small cell lung carcinoma.

SNTX | N-terminal Telopeptide, Serum

This test is intended to be used for monitoring effectiveness of antiresorptive therapy in patients treated for osteoporosis or other metabolic bone disorders.

SSP | Sporothrix Antibody, Serum

This test is intended for aiding in the diagnosis of extracutaneous sporotrichosis.

SSPC | Sporothrix Antibody, Spinal Fluid

This test is intended for aiding in the diagnosis of extracutaneous sporotrichosis.

SV40 | SV40 Immunostain, Technical Component Only

This test is intended to be used for identifying BK or JC polyomavirus.

TB1LN | Antimicrobial Susceptibility, Mycobacterium tuberculosis Complex, First Line, Varies

This test is intended to be used for rapid, qualitative susceptibility testing of Mycobacterium tuberculosis complex isolates growing in pure culture as well as confirming the emergence of drug resistance.

TBPZA | Susceptibility, Mycobacterium tuberculosis Complex, Pyrazinamide, Varies

This test is intended for susceptibility testing of Mycobacterium tuberculosis complex isolates growing in pure culture against pyrazinamide.

VZIKM | Zika Virus, IgM Antibody Capture ELISA, Serum

This test is intended to be used for screening for the presence of IgM-class antibodies to Zika virus.
This test is not recommended for asymptomatic couples attempting conception.

In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories:

Samantha Rossi (@samantharossi)

Samantha Rossi

Samantha Rossi is a Digital Marketing Manager at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.